O	0	13	Determination	Determination	NN	B-NP
O	14	16	of	of	IN	B-PP
O	17	27	eprosartan	eprosartan	NN	B-NP
O	28	30	in	in	IN	B-PP
O	31	36	human	human	JJ	B-NP
B-Organism_substance	37	43	plasma	plasma	NN	I-NP
O	44	47	and	and	CC	I-NP
B-Organism_substance	48	53	urine	urine	NN	I-NP
O	54	56	by	by	IN	B-PP
O	57	59	LC	LC	NN	B-NP
O	59	60	/	/	SYM	B-NP
O	60	62	MS	MS	NN	I-NP
O	62	63	/	/	SYM	I-NP
O	63	65	MS	MS	NN	I-NP
O	65	66	.	.	.	O

O	67	68	A	A	DT	B-NP
O	69	76	protein	protein	NN	I-NP
O	77	90	precipitation	precipitation	NN	I-NP
O	90	91	,	,	,	O
O	92	98	liquid	liquid	NN	B-NP
O	99	113	chromatography	chromatography	NN	I-NP
O	113	114	/	/	SYM	B-NP
O	114	120	tandem	tandem	JJ	I-NP
O	121	125	mass	mass	NN	I-NP
O	126	138	spectrometry	spectrometry	NN	I-NP
O	139	140	(	(	(	O
O	140	142	LC	LC	NN	B-NP
O	142	143	/	/	SYM	B-NP
O	143	145	MS	MS	NN	I-NP
O	145	146	/	/	SYM	I-NP
O	146	148	MS	MS	NN	I-NP
O	148	149	)	)	)	O
O	150	156	method	method	NN	B-NP
O	157	160	has	have	VBZ	B-VP
O	161	165	been	be	VBN	I-VP
O	166	175	developed	develop	VBN	I-VP
O	176	179	and	and	CC	I-VP
O	180	189	validated	validate	VBN	I-VP
O	190	193	for	for	IN	B-PP
O	194	197	the	the	DT	B-NP
O	198	211	determination	determination	NN	I-NP
O	212	214	of	of	IN	B-PP
O	215	225	eprosartan	eprosartan	NN	B-NP
O	226	228	in	in	IN	B-PP
O	229	234	human	human	JJ	B-NP
B-Organism_substance	235	241	plasma	plasma	NN	I-NP
O	242	245	and	and	CC	I-NP
B-Organism_substance	246	251	urine	urine	NN	I-NP
O	251	252	.	.	.	O

O	253	256	The	The	DT	B-NP
O	257	264	solvent	solvent	JJ	I-NP
O	265	271	system	system	NN	I-NP
O	272	276	also	also	RB	B-ADVP
O	277	283	served	serve	VBD	B-VP
O	284	286	as	as	IN	B-PP
O	287	288	a	a	DT	B-NP
O	289	296	protein	protein	NN	I-NP
O	297	310	precipitation	precipitation	NN	I-NP
O	311	318	reagent	reagent	NN	I-NP
O	318	319	.	.	.	O

O	320	323	The	The	DT	B-NP
O	324	339	chromatographic	chromatographic	JJ	I-NP
O	340	350	separation	separation	NN	I-NP
O	351	354	was	be	VBD	B-VP
O	355	363	achieved	achieve	VBN	I-VP
O	364	366	on	on	IN	B-PP
O	367	368	a	a	DT	B-NP
O	369	376	CAPCELL	CAPCELL	NN	I-NP
O	377	380	PAK	PAK	NN	I-NP
O	381	384	C18	C18	NN	I-NP
O	385	391	column	column	NN	I-NP
O	392	393	(	(	(	O
O	393	395	50	50	CD	B-NP
O	396	400	mmx2	mmx2	NN	I-NP
O	400	401	.	.	.	O
O	401	402	0	0	CD	B-NP
O	403	405	mm	mm	NN	I-NP
O	405	406	,	,	,	O
O	407	408	5	5	CD	B-NP
O	409	415	microm	microm	NN	I-NP
O	415	416	,	,	,	O
O	417	425	Shiseido	Shiseido	NNP	B-NP
O	425	426	)	)	)	O
O	426	427	.	.	.	O

O	428	429	A	A	DT	B-NP
O	430	436	mobile	mobile	JJ	I-NP
O	437	442	phase	phase	NN	I-NP
O	443	446	was	be	VBD	B-VP
O	447	456	consisted	consist	VBN	I-VP
O	457	459	of	of	IN	B-PP
O	460	461	0	0	CD	B-NP
O	461	462	.	.	.	O
O	462	463	5	5	CD	B-NP
O	463	464	%	%	NN	I-NP
O	465	471	formic	formic	JJ	I-NP
O	472	476	acid	acid	NN	I-NP
O	477	479	in	in	IN	B-PP
O	480	485	water	water	NN	B-NP
O	486	489	and	and	CC	O
O	490	491	0	0	CD	B-NP
O	491	492	.	.	.	O
O	492	493	5	5	CD	B-NP
O	493	494	%	%	NN	I-NP
O	495	501	formic	formic	JJ	I-NP
O	502	506	acid	acid	NN	I-NP
O	507	509	in	in	IN	B-PP
O	510	522	acetonitrile	acetonitrile	NN	B-NP
O	523	524	(	(	(	O
O	524	526	72	72	CD	B-NP
O	526	527	:	:	:	O
O	527	529	28	28	CD	B-NP
O	529	530	)	)	)	O
O	530	531	.	.	.	O

O	532	541	Detection	Detection	NN	B-NP
O	542	545	was	be	VBD	B-VP
O	546	548	by	by	IN	B-PP
O	549	557	positive	positive	JJ	B-NP
O	558	561	ion	ion	NN	I-NP
O	562	574	electrospray	electrospray	NN	I-NP
O	575	581	tandem	tandem	JJ	I-NP
O	582	586	mass	mass	NN	I-NP
O	587	599	spectrometry	spectrometry	NN	I-NP
O	600	602	on	on	IN	B-PP
O	603	604	a	a	DT	B-NP
O	605	610	Sciex	Sciex	NNP	I-NP
O	611	618	API3000	API3000	NN	I-NP
O	618	619	.	.	.	O

O	620	623	The	The	DT	B-NP
O	624	632	standard	standard	JJ	I-NP
O	633	639	curves	curve	NNS	I-NP
O	639	640	,	,	,	O
O	641	646	which	which	WDT	B-NP
O	647	653	ranged	range	VBD	B-VP
O	654	658	from	from	IN	B-PP
O	659	660	5	5	CD	B-NP
O	661	663	to	to	TO	I-NP
O	664	668	2000	2000	CD	I-NP
O	669	671	ng	ng	NN	I-NP
O	671	672	/	/	SYM	B-NP
O	672	674	mL	mL	NN	I-NP
O	675	677	in	in	IN	B-PP
O	678	683	human	human	JJ	B-NP
B-Organism_substance	684	690	plasma	plasma	NN	I-NP
O	691	694	and	and	CC	B-PP
O	695	699	from	from	IN	B-PP
O	700	701	0	0	CD	B-NP
O	701	702	.	.	.	O
O	702	704	25	25	CD	B-NP
O	705	707	to	to	TO	I-NP
O	708	710	50	50	CD	I-NP
O	711	717	microg	microg	NN	I-NP
O	717	718	/	/	SYM	B-NP
O	718	720	mL	mL	NN	I-NP
O	721	723	in	in	IN	B-PP
B-Organism_substance	724	729	urine	urine	NN	B-NP
O	729	730	,	,	,	O
O	731	735	were	be	VBD	B-VP
O	736	742	fitted	fit	VBN	I-VP
O	743	745	to	to	TO	B-PP
O	746	747	a	a	DT	B-NP
O	748	749	1	1	CD	I-NP
O	749	750	/	/	SYM	O
O	750	751	x	x	SYM	O
O	752	760	weighted	weighted	JJ	B-NP
O	761	770	quadratic	quadratic	JJ	I-NP
O	771	781	regression	regression	NN	I-NP
O	782	787	model	model	NN	I-NP
O	787	788	.	.	.	O

O	789	792	The	The	DT	B-NP
O	793	799	method	method	NN	I-NP
O	800	806	proved	prove	VBD	B-VP
O	807	809	to	to	TO	I-VP
O	810	812	be	be	VB	I-VP
O	813	821	accurate	accurate	JJ	B-ADJP
O	821	822	,	,	,	O
O	823	831	specific	specific	JJ	B-ADJP
O	832	835	and	and	CC	O
O	836	845	sensitive	sensitive	JJ	B-ADJP
O	846	852	enough	enough	RB	I-ADJP
O	853	855	to	to	TO	B-VP
O	856	858	be	be	VB	I-VP
O	859	871	successfully	successfully	RB	I-VP
O	872	879	applied	apply	VBN	I-VP
O	880	882	to	to	TO	B-PP
O	883	884	a	a	DT	B-NP
O	885	900	pharmacokinetic	pharmacokinetic	JJ	I-NP
O	901	906	study	study	NN	I-NP
O	906	907	.	.	.	O

